Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma

Alberto Papi,Mario Castro,Jonathan Corren,Ian D. Pavord,Yuji Tohda, Arman Altincatal,Nami Pandit-Abid,Elizabeth Laws,Bolanle Akinlade,Leda P. Mannent,Rebecca Gall,Juby A. Jacob-Nara,Yamo Deniz,Paul J. Rowe,David J. Lederer, Megan Hardin

Respiratory Medicine（2024）

引用 0|浏览1

暂无评分

摘要

•This analysis included patients ≥12 years old with moderate-to-severe type 2 asthma.•Dupilumab sustained improvements in several spirometric measures for up to 3 years.•Pre-bronchodilator FVC, similarly to FEV1, improved in the long term.•FEV1 slope results suggest that dupilumab may prevent lung function loss over time.•Dupilumab may impact long-term small/large airway function and airflow obstruction.

查看译文

关键词

Dupilumab,Moderate-to-severe asthma,Lung function,Type 2 inflammation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要